Insilico study of anti-carcinogenic lysyl oxidase-like 2 inhibitors
Abstract Lysyl oxidase homolog 2 (LOXL2), also known as lysyl oxidase-like protein 2 is
recently been explored as regulator of carcinogenesis and has been shown to be involved
in tumor progression and metastasis of several carcinomas. Therefore LOXL2 has been
considered as potential therapeutic target. Doing so, its inhibitors as new chemotherapeutic
lead molecules: 4-amino-5-(2-hydroxyphenyl)-1, 2, 4-triazol-3-thione (2a) and 4-(2-
hydroxybenzalidine) amine-5-(2-hydroxy) phenyl-1, 2, 4-triazole-3-thiol (2b) are synthesized …
recently been explored as regulator of carcinogenesis and has been shown to be involved
in tumor progression and metastasis of several carcinomas. Therefore LOXL2 has been
considered as potential therapeutic target. Doing so, its inhibitors as new chemotherapeutic
lead molecules: 4-amino-5-(2-hydroxyphenyl)-1, 2, 4-triazol-3-thione (2a) and 4-(2-
hydroxybenzalidine) amine-5-(2-hydroxy) phenyl-1, 2, 4-triazole-3-thiol (2b) are synthesized …